Connect your AI

TTRX TTRX Net Investment in Lease

Net Investment in Lease at other companies

Journey Medical CorporationDERM

——

PTH

Pelthos Therapeutics Inc.PTHS

——

Celldex TherapeuticsCLDX

——

Arcutis Biotherapeutics, Inc.ARQT

——

Kymera TherapeuticsKYMR

——

PVL

Palvella TherapeuticsPVLA

——

Other financials

Income statement

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

Operating cash flow-$1.6M-448%

Valuation

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TTRX's net investment in lease?: TTRX (TTRX) reported net investment in lease of $67.57K in Q1 2026.